GlucoTrack, Inc.
GCTKHealthcareNASDAQMedical Devices · Last scanned Oct 24, 2026
Scan Results
Daily timeframeGlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The $477K market capitalization puts GCTK squarely in micro-cap range for its industry. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.
Market Cap
$477,436
Beta
0.73
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-246.30
EPS (Fwd)
—
ROE
-620.6%
ROA
-164.5%
Cash
$1.1M
Total Debt
$2.0M
Free CF
-$10.4M
52W Change
-99.6%
Annual Financials
Cash vs Debt
Where GCTK stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, GCTK finished 90.31% below its 150-day moving average ($7.12) and 95.15% below its 200-day moving average ($14.22). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GCTK overbought or oversold?
At the October 20, 2026 close, GCTK's RSI(14) was 12.2, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
GlucoTrack, Inc. carries $2.0M in total debt against $1.1M in cash reserves — debt is roughly 1.7x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$10.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -620.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for GlucoTrack, Inc. and its sector.